Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.
The company believes Indian clinicians and patients will be receptive to this new technology, but only in an efficient and actionable form.
Samples from metastatic melanoma patients treated sequentially with immunotherapies targeting CTLA4 and PD-1 pointed to response-related tumor features.
The study compared five methods, including three based on Roche test kits and reagents, and suggested that a multiplexed test may be best to avoid false-negative results.
The company has partnered with the German National Center for Tumor Diseases to identify biomarkers for predicting response to immunotherapy in melanoma patients.
In Science this week: study of the functions of long non-coding RNAs, and more.
In PNAS this week: recurrent deletions in mesothelioma patients, mutagenesis screen for genes working with PTEN in triple-negative breast cancer, and more.
Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The Taiwanese research team that developed the method showed in a new study that it could better detect BRAF mutations than conventional PCR plus Sanger sequencing.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.